利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

128 条记录 (耗时 0.03 秒)

    MODIFIED CELLS THAT CO-EXPRESS BLIMP1 AND A REPORTER MOLECULE AND METHODS OF USING THE SAME
    91.
    发明申请
    MODIFIED CELLS THAT CO-EXPRESS BLIMP1 AND A REPORTER MOLECULE AND METHODS OF USING THE SAME 审中-公开
    共表达BLIMP1和报告分子的修饰细胞及其使用方法

    公开(公告)号：WO2005078098A1

    公开(公告)日：2005-08-25

    申请号：PCT/AU2005/000168

    申请日：2005-02-11

    申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH ,  KALLIES, Axel ,  HASBOLD, Jhagvaral ,  TARLINTON, David ,  CORCORAN, Lynn ,  HODGKIN, Philip, Desmond ,  NUTT, Stephen, Laurence

    发明人： KALLIES, Axel ,  HASBOLD, Jhagvaral ,  TARLINTON, David ,  CORCORAN, Lynn ,  HODGKIN, Philip, Desmond ,  NUTT, Stephen, Laurence

    IPC分类号： C12N15/12

    CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  C12N2800/30 ,  C12N2840/203 ,  C12N2840/44

    摘要： In one aspect, the present invention provides a genetically modified cell or non-human organism comprising such cells comprising modified genetic material which when expressed produces a polypeptide co-expressed with a reporter molecule and wherein the polypeptide is associated with terminal differentiation of a haematopoietic cell. Preferably, the genetic material gene is a Blimp allele or a part, fragment or functional form thereof. Furthermore, the identification of the reporter molecule in B-cell lineage cells indicates that such cells are committed to differentiate or have differentiated into ASC. Alternatively, reporter molecule activity in cells of a T cell lineage indicates that these cells are activated. Thus, as described herein, the presence of Blimp in a lymphocyte indicates that the cell is terminally differentiated or is committed to terminal differentiation. Exemplary T-cells include CD4 + T-cells and CD8 + T-cells and exemplary B-cells are ASC.

    摘要翻译： 在一个方面，本发明提供了一种转基因细胞或非人生物，其包含这样的细胞，其包含经修饰的遗传物质，其在表达时产生与报告分子共表达的多肽，并且其中所述多肽与造血细胞的末端分化相关 。 优选地，遗传物质基因是Blimp等位基因或其部分，片段或功能形式。 此外，B细胞谱系细胞中报道分子的鉴定表明，这样的细胞被致力于分化或分化为ASC。 或者，T细胞谱系的细胞中的报告分子活性表明这些细胞被活化。 因此，如本文所述，Blimp在淋巴细胞中的存在表明细胞是终末分化的或致力于终末分化。 示例性T细胞包括CD4 + T细胞和CD8 + T细胞，示例性B细胞是ASC。

    METHOD OF SELECTING ANIMAL MODELS FROM ANIMALS WHICH HAVE BEEN SUBJECT TO MUTAGENESIS, AND THE USE OF MYB TRANSCRIPTION FACTORS FOR SCREENING
    92.
    发明申请
    METHOD OF SELECTING ANIMAL MODELS FROM ANIMALS WHICH HAVE BEEN SUBJECT TO MUTAGENESIS, AND THE USE OF MYB TRANSCRIPTION FACTORS FOR SCREENING 审中-公开
    从动物模型中选择动物模型的方法，以及使用MYB转录因子进行筛选

    公开(公告)号：WO2005020677A1

    公开(公告)日：2005-03-10

    申请号：PCT/AU2004/001167

    申请日：2004-08-27

    申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH ,  HILTON, Douglas, J. ,  ALEXANDER, Warren, S. ,  CARPINELLI, Marina

    发明人： HILTON, Douglas, J. ,  ALEXANDER, Warren, S. ,  CARPINELLI, Marina

    IPC分类号： A01K67/00

    CPC分类号： A01K67/027 ,  A01K67/0275 ,  A01K2217/03 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0306 ,  C12N15/8509

    摘要： The present invention relates generally to target molecules for potential therapeutic and/or prophylactic intervention. More particularly, the present invention provides a physiological assessment system in the form of vertebrate animal models to identify genetic or proteinaceous drug targets therein associated with a disease or a particular condition or phenotype. In an illustrative embodiment, target molecules associated with modulating platelet levels and ameliorating the symptoms of thrombocytopenia are described. The target molecules are useful as therapeutic and/or prophylactic agents such as in antisense or iRNA form. The present invention also relates to the application of these drug targets in the identification or development of therapeutic and/or prophylactic agents which modulate the functional activity of the drug target or its interacting network of molecules.

    摘要翻译： 本发明一般涉及用于潜在治疗和/或预防性干预的靶分子。 更具体地，本发明提供了脊椎动物模型形式的生物学评估系统，以鉴定其中与疾病或特定病症或表型有关的遗传或蛋白质药物靶标。 在说明性实施方案中，描述了与调节血小板水平相关并且改善血小板减少症状的靶分子。 靶分子可用作治疗和/或预防剂如反义或iRNA形式。 本发明还涉及这些药物靶标在鉴定或开发调节药物靶标或其相互作用的分子网络的功能活性的治疗和/或预防剂中的应用。

    IMMUNOGENIC COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
    94.
    发明申请
    IMMUNOGENIC COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF 审中-公开
    免疫组化及其诊断和治疗用途

    公开(公告)号：WO2004011026A1

    公开(公告)日：2004-02-05

    申请号：PCT/AU2003/000944

    申请日：2003-07-25

    申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH ,  SCHOFIELD, Louis

    发明人： SCHOFIELD, Louis

    IPC分类号： A61K39/015

    CPC分类号： C07K16/205 ,  A61K31/739 ,  A61K39/015 ,  A61K2039/505 ,  Y02A50/412

    摘要： The present invention relates generally to a method of eliciting or otherwise inducing an immune response to a microorganism and compositions for use therein. More particularly, the present invention relates to a method of inducing an immune response to a parasite utilising an immunogenic composition comprising a glycosylphosphatidylinositol (referred to herein as "GPI") inositolglycan domain or its derivative or equivalent. The present invention is useful, inter alia , as a prophylactic and/or therapeutic treatment for microorganism infections of mammals such as, for example, parasite infections and in particular infection by Plasmodium species. In another aspect the invention provides a method of diagnosing, monitoring, screening for or otherwise qualitatively or quantitatively assessing an immune response to a microorganism and, in particular, a parasite. More particularly, this aspect of the present invention is directed to assessing said immune response utilising a GPI inositoglycan domain or its derivative or equivalent. The development of this aspect of the present invention facilitates, inter alia , the qualitative and/or quantitative analysis of anti-GPI antibodies in a biological sample, the identification and/or isolation of unique specificities of antibodies (such as those which bind a parasite derived toxin or the parasite itself), epitope specific screening or the rational design of immunogenic molecules and the generation , thereby, of functionally effective immunointeractive molecules.

    摘要翻译： 本发明一般涉及引发或以其它方式诱导对微生物的免疫应答的方法及其中使用的组合物。 更具体地说，本发明涉及利用包含糖基磷脂酰肌醇（本文称为“GPI”）肌醇聚糖结构域或其衍生物或等同物的免疫原性组合物诱导对寄生虫的免疫应答的方法。 本发明尤其可用作哺乳动物微生物感染的预防和/或治疗方法，例如寄生虫感染，特别是疟原虫感染。 在另一方面，本发明提供了诊断，监测，筛选或以其他方式定性或定量评估对微生物，特别是寄生虫的免疫应答的方法。 更具体地，本发明的这个方面是针对利用GPI肌凝聚糖结构域或其衍生物或等同物来评估所述免疫应答的。 本发明的该方面的发展特别有利于生物样品中抗GPI抗体的定性和/或定量分析，鉴定和/或分离抗体的独特特异性（例如结合寄生虫的那些特异性 衍生的毒素或寄生虫本身），表位特异性筛选或免疫原性分子的合理设计以及功能有效的免疫相互作用分子的产生。

    LMT TURMOR SUPPRESSOR GENE
    95.
    发明申请
    LMT TURMOR SUPPRESSOR GENE 审中-公开
    LMT TURMOR抑制基因

    公开(公告)号：WO2003066869A1

    公开(公告)日：2003-08-14

    申请号：PCT/AU2003/000126

    申请日：2003-02-07

    申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH ,  COOK, Wendy, Dianne ,  MCCAW, Benjamin, John

    发明人： COOK, Wendy, Dianne ,  MCCAW, Benjamin, John

    IPC分类号： C12N015/12

    CPC分类号： C07K14/4703 ,  A01K2217/05

    摘要： The present invention relates generally to the field of cancer therapy and cancer diagnostics and to agents useful therefor. More particularly, the present invention provides a novel tumor suppressor gene, an expression product including a polypeptide or protein encoded thereby and nucleic acid probes and primers and peptide fragments characteristic of the tumor suppressor gene or its expression product or mutants or derivatives thereof. The present invention further provides molecules generated through combinatorial chemistry or rational chemical synthesis or identified following screening of chemical libraries or natural sources which augment or otherwise facilitate the activity or function of the tumor suppressor gene or its expression product and in particular in cells which carry a deletion or other mutation including a gene silencing event in one or both alleles of the tumor suppressor gene. The present invention provides diagnostic agents to detect the presence or absence of the tumor suppressor gene or the presence or absence of an expressible tumor suppressor gene or the presence or absence of an expression product of the tumor suppressor gene useful in determining the likelihood of development of a tumor in a vertebrate animal such as mammal and in particular a human. The present invention further provides genetically modified animals carrying cells in which one or both alleles of the tumor suppressor gene are deleted or mutated or where expression of the gene is otherwise silenced.

    摘要翻译： 本发明一般涉及癌症治疗和癌症诊断领域以及对此有用的药剂。 更具体地，本发明提供了一种新的肿瘤抑制基因，包括其编码的多肽或蛋白质的表达产物，以及肿瘤抑制基因或其表达产物或其突变体或衍生物的特征性核酸探针和引物和肽片段。 本发明进一步提供通过组合化学或合理化学合成产生的分子，或鉴定后续筛选化学文库或天然来源，其增强或以其它方式促进肿瘤抑制基因或其表达产物的活性或功能，特别是在携带 缺失或其他突变，包括肿瘤抑制基因的一个或两个等位基因中的基因沉默事件。 本发明提供了用于检测肿瘤抑制基因的存在或不存在的诊断剂或可表达的肿瘤抑制基因的存在或不存在，或者是否存在可用于确定发展的可能性的肿瘤抑制基因的表达产物 脊椎动物如哺乳动物，特别是人类的肿瘤。 本发明还提供了携带细胞的遗传修饰的动物，其中肿瘤抑制基因的一个或两个等位基因被缺失或突变，或者其中基因的表达被沉默。